Therapeutic Solutions International, Inc. Announces Memorandum of Understanding With ZYPPAH, Inc.

OCEANSIDE, CA--(Marketwired - Aug 6, 2013) -  Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today a collaboration with ZYPPAH, Inc., in efforts to promote ZYPPAH's professional education classes wherein TSI's Sleepwell^® product will be included as a therapeutic option and recommendation for dentists attending ZYPPAH's professional education classes.

"Until now, most patients diagnosed with mild to moderate obstructive sleep apnea (OSA) have been treated with a standard mandibular advancement device (MAD), continuous positive airway pressure (CPAP) machine, or surgery," said Dr. Jonathan Greenburg, CEO of ZYPPAH, Inc., who also stated, "This agreement between ZYPPAH and TSI to provide TSI's Sleepwell® product enhanced with the patent-pending ZYPPAH® elastic, will offer dentists and their patients a new standard of treatment for both snoring and mild to moderate sleep apnea."

Dr. Barry Glassman, Vice President of Education and Training, said, "We have been truly impressed with the vision of Dr. Jonathan Greenburg and his team at ZYPPAH and thrilled that TSI will be playing a key role not only in education but in future growth and decision making. TSI's Sleepwell appliance has been added as a top level choice in the appliance armamentarium and I will be guiding the educational program. There is no question that this association will benefit both ZYPPAH and TSI."

Tim Dixon, CEO of TSI, stated, "This agreement with ZYPPAH and Dr. Greenburg will help TSI to promote the awareness of 'Sleepwell^®' within the professional dental community, and will beneficially aid the sale of Sleepwell hardware to licensed dentists and dental labs in the United States."

Therapeutic Solutions International is also a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X^® and AMPSA CS^®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X^® and AMPSA CS^® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today. Therapeutic Solutions International is the exclusive United States distributor of "Sleepwell™" hardware used to manufacture the "Sleepwell^®" dental appliance for snoring and mild to moderate obstructive sleep apnea.

About ZYPPAH, Inc.

ZYPPAH Rx is an FDA-cleared, self-molded, boil-and-bite oral appliance that is effective, safe and easy to use. Product information can be viewed at www.zyppah.com

About Therapeutic Solutions International, Inc.

The Company's corporate website is www.therapeuticsolutionsint.com. Non-US dentists and physicians can order our AMPSA products at www.ordertsoi.com. For the Sleepwell^® product, clinical data can be viewed at www.sleepwelldevice.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at www.sec.gov.